HRMY — Harmony Biosciences Holdings, Inc.

Harmony Biosciences (HRMY) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Net Product Revenue: $243.8 million, up 21% from $201.3 million in Q4 2024.
• Full Year 2025 Net Product Revenue: $868.5 million, marking six consecutive years of revenue growth and profitability.
• Non-GAAP Adjusted Net Income (Q4 2025): $33.4 million ($0.57 per diluted share), down from $64.2 million ($1.10 per diluted share) in Q4 2024.
• Operating Expenses (Q4 2025): $136.7 million, up from $91.1 million in Q4 2024, primarily due to R&D investments and litigation expenses.
• Cash Position: $882.5 million in cash, cash equivalents, and investments, with $348.2 million generated from operations in 2025.

2. Strategic Updates and Business Highlights

• WAKIX Performance: Continued strong demand with approximately 400+ average patient adds for three consecutive quarters, totaling around 8,500 average patients.
• Pediatric Approval: WAKIX received FDA approval for treating cataplexy in pediatric patients aged 6 and older, expanding its market potential.
• Next-Generation Products: Advancements in the pitolisant franchise with plans for NDA submissions for pitolisant GR in Q2 2026 and pitolisant HD targeting PDUFA in 2028.
• Pipeline Development: Five ongoing Phase III registrational trials across distinct CNS indications, with multiple catalysts expected over the next few years.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance for WAKIX: Expected to reach blockbuster status with net revenue between $1 billion and $1.04 billion.
• Patient Growth Expectations: Continued momentum from 2025 patient adds is anticipated, with typical seasonal dynamics expected in Q1 2026.
• Investment in R&D: Significant increases in R&D expenses are expected as the company advances its pipeline.

4. Bad News, Challenges, or Points of Concern

• Decline in Non-GAAP Net Income: The decrease in adjusted net income reflects increased operating expenses and investments.
• Litigation Risks: Ongoing ANDA litigation with generic filers poses a risk, although recent settlements have pushed potential generic entry to March 2030, contingent on pediatric exclusivity.
• Competitive Pressures: The company faces competition in the CNS market, particularly in narcolepsy and idiopathic hypersomnia, as other companies are also enrolling patients in similar studies.

5. Notable Q&A Insights

• EPX-100 for Dravet Syndrome: Discussion on baseline seizure rates and competitive positioning highlighted the drug's efficacy and tolerability compared to existing treatments.
• Orexin-2 Receptor Agonist Development: Plans for mid-2026 data release and potential broader indications beyond narcolepsy and idiopathic hypersomnia were discussed.
• Sales Force Expansion: A 20% increase in field-based teams is aimed at enhancing market presence, with expected impacts to be seen post-hiring.
• Pediatric Cataplexy Opportunity: The pediatric population represents about 5% of the narcolepsy market, and the approval is expected to enhance WAKIX's positioning among healthcare providers.

Overall, Harmony Biosciences demonstrated strong financial performance and strategic advancements in 2025, while navigating challenges related to litigation and competitive pressures in the CNS market. The company is well-positioned for growth in 2026 with a focus on expanding its product offerings and pipeline.